ASV and Heart Failure: The Contraindication and the Evidence Behind It
One trial found adaptive servo-ventilation increased cardiovascular mortality in heart failure patients with central apnea, and it became a contraindication. A pooled analysis of four trials now calls the question inconclusive. The restriction still stands, and here is why both things are true.
This page exists because the usual logic of this site — find the mechanism, treat the obstruction — produced one of sleep medicine's clearest cautionary results.
If you have heart failure with a reduced ejection fraction and predominantly central sleep apnea, adaptive servo-ventilation is contraindicated. That is the clinical position, it has been since 2015, and nothing below is a reason to work around it. What follows is why the restriction exists and why the evidence underneath it is less settled than the headline suggests.
What ASV is, and why it looked so promising
Adaptive servo-ventilation is a sophisticated form of positive airway pressure. Rather than holding one pressure or switching between two, it monitors your breathing pattern continuously and varies pressure support breath by breath to smooth out the irregularity.
That is aimed at a specific problem. Central sleep apnea is not an obstruction — the airway is open and the brain is not sending a reliable breathing signal. In heart failure this often takes the form of Cheyne-Stokes respiration, a crescendo-decrescendo pattern of deepening and fading breaths. ASV was designed to damp exactly that oscillation, and it does: it is genuinely effective at normalising the breathing pattern.
Which made the result that followed so unwelcome.
The finding that changed practice
A large randomised trial in patients with heart failure, reduced ejection fraction and predominant central apnea found increased cardiovascular mortality in the group receiving ASV. Not a null result — harm. The trial was stopped, a field safety notice followed, and ASV became contraindicated in that population.
The mechanism was never fully established, and remains debated. Candidate explanations include the effects of positive intrathoracic pressure on an already compromised failing heart, and the possibility that Cheyne-Stokes respiration is partly compensatory in this group rather than purely harmful — meaning that suppressing it removes something the body was doing on purpose.
That second idea is uncomfortable and worth sitting with. It is the clearest example in this field of a treatment that successfully fixed the number it targeted and made patients worse.
What the pooled evidence now says
A 2025 meta-analysis with trial sequential analysis gathered the randomised evidence — four RCTs — on ASV and cardiovascular mortality in this population.
The pooled odds ratio for cardiovascular mortality was 0.92 (95% CI 0.46 to 1.81, p=0.80, I²=54%).
So the pooled point estimate sits essentially at no difference, with a confidence interval wide enough to include substantial benefit and substantial harm. The trial sequential analysis makes the position explicit: the Z-curve stayed inside the "not statistically significant" zone and reached neither the required information size nor the futility boundary. The authors' word for the result is "inconclusive."
That is not a retraction of the original finding. It means that across all four trials together, the evidence cannot currently establish either harm or safety, and more randomised data is needed. Reviews continue to ask where the field now stands and how central apnea in heart failure should be treated at all.
Evidence tier 2, in an unusual direction. The contraindication rests on one large trial showing harm; the pooled analysis cannot confirm or refute it. When a safety signal is unresolved, the precautionary reading governs — which is why the restriction has not been lifted.
What this means practically
It does not apply to obstructive sleep apnea. This is the single most important clarification. If you have ordinary obstructive apnea, none of this concerns you, and CPAP's evidence base is unaffected. ASV is a specialist device for a specialist problem.
It applies to a specific combination: heart failure with reduced ejection fraction, plus predominantly central apnea. Change either element and the picture changes.
Central apnea in heart failure still needs managing — the contraindication removed an option, it did not remove the problem. That management is a cardiology and sleep medicine decision involving optimising the heart failure treatment itself, and in some cases other forms of pressure therapy or phrenic nerve stimulation. What central sleep apnea is and how it differs.
Do not self-select ASV, and do not infer from "inconclusive" that the restriction is outdated. An unresolved safety signal in a vulnerable population is a reason for caution, not for a trial of one. If you are on any form of pressure therapy and have heart failure, the machine type is a question for the clinician managing both. How fixed, auto-adjusting and bilevel pressure differ.
And the general lesson transfers. Normalising a measurement is not the same as helping the patient. It is the same caution that applies to every device on this site that quietens snoring without opening an airway. What untreated apnea accumulates, and what treating it does not fix, and snoring versus apnea.